Non-Alcoholic Fatty Liver Disease Clinical Trial
Official title:
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) and Elevated Alanine Aminotransferase (ALT)
Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | December 30, 2025 |
Est. primary completion date | December 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: Inclusion Criteria for all patients: 1. Age 18-75 years 2. A clinical diagnosis of non-alcoholic fatty liver disease. 3. Alanine aminotransferase (ALT) levels =60 IU/mL 4. Laboratory tests as defined below: - Platelets > 100,000/dL - Total bilirubin < 2 mg/dL - Creatinine < 1.6 mg/dL - Inclusion Criteria for Group 1: diabetic patients 1. At least one of the following: - Fasting blood sugar = 126mg/dL - Hemoglobin A1c (HgA1c) of > 6.5% - 2-hour plasma glucose level of > 200mg/dL during a glucose tolerance test - Receiving treatment with insulin sensitizing drugs (metformin) or sulfonylureas (glipizide, etc.) 3. Inclusion Criteria for Group 2: Non-diabetic patients with insulin resistance (must have both) - Fasting blood glucose of 100-125 mg/dL and - Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score >3.0 Exclusion Criteria: 1. Evidence of liver disease other than non-alcoholic fatty liver disease or non-alcoholic steatohepatitis 2. Alcohol consumption of more than 12g/d (1 drink) for females or more than 24g/day (2 drinks) for males, for 3 months during the past year 3. Active substance abuse within the past year 4. Prior or ongoing use of injectable insulin 5. Use of oral corticosteroids within the prior 30 days 6. Hospitalization within the past 14 days 7. Known HIV infection 8. HgA1c >10% 9. Known heart failure of New York Heart Association class 2, 3, or 4 10. Any condition, which in the opinion of the investigator, would impede compliance or hinder the completion of the study 11. History of allergic reactions attributed to compounds of similar chemical or biologic composition to betaine 12. Current use of betaine or S-adenosylmethionine supplements, or refusal to abstain from their use during the study 13. Known cystathionine beta-synthase (CBS) deficiency. 14. Pregnancy or refusal to use birth control measures or breast feeding |
Country | Name | City | State |
---|---|---|---|
United States | VA Long Beach Healthcare System | Long Beach | California |
Lead Sponsor | Collaborator |
---|---|
Southern California Institute for Research and Education |
United States,
Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999 Mar;29(3):664-9. doi: 10.1002/hep.510290347. — View Citation
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999 Jun;116(6):1413-9. doi: 10.1016/s0016-5085(99)70506-8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in alanine aminotransferase (ALT) level in all study participants | Compare the week 12 ALT levels with the baseline ALT in study patients. Comparison will be performed using a paired t-test. | after 12 weeks of Betaine | |
Secondary | Compare changes in alanine aminotransferase (ALT) level in both cohorts | A Paired T test analysis will compare changes in ALT levels between Patients with NIDDM (cohort 1) and Patients without NIDDM (cohort 2) | after 12 weeks of Betaine |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |